The General Hospital Corporation

The University of North Carolina at Chapel Hill

Baylor College of Medicine

Gianpietro Dotti

Soldano Ferrone

Xinhui Wang

Malcolm K Brenner

Stephen M G Gottschalk

Leonid S Metelitsa

Cristina Ferrone

Nabil M Ahmed

Rihe Liu

Carlos A Ramos

Hongwei Du

Claudia Rossig

Jiyoung Ahn Morrison

Hannah Reid Hudson

Elena Dukhovlinova

JingJing Li

Zakaria Grada

Daofeng Liu

Andras Heczey

Barbara Savoldo

Wenpeng Li

Stephen MG Gottschalk

The present invention provides a chimeric antigen receptor (CAR) that recognizes CSPG4 as well as methods of use in the treatment of diseases and disorders.

Methods and compositions for chimeric antigen receptor targeting cancer cells

Provided herein are biepitopic or bispecific chimeric antigen receptors. The chimeric antigen receptors comprise a combination of single domain antibody mimics. The single domain antibody mimics may be monobodies, affibodies, or DARPins. The disclosed chimeric antigen receptors may recognize two different epitopes of the same tumor antigen. For example, the chimeric antigen receptor may recognize two different epitopes of HER-2 or EGFR. The disclosed chimeric antigen receptors may recognize two epitopes of two different tumor antigens. For example, the chimeric antigen receptor may recognize HER-2 and EGFR. The disclosed chimeric antigen receptors may be expressed in immune cells for use in cancer immunotherapy.

Highly modular biepitopic and bispecific CAR-T cells for cancer immunotherapy

Embodiments of the disclosure include methods and compositions related to chimeric antigen receptors (CAR) that target chondroitin sulfate proteoglycan-4 (CSPG4). T cells transduced with a CSPG4-specific CAR are effective for inhibition of particular cancer cells that express CSPG4. In certain embodiments, the cancer is melanoma, breast cancer, head and neck cancer, mesothelioma, glioblastoma, or renal cancer.

CSGP4&#x2014;specific chimeric antigen receptor for cancer

The present invention provides a chimeric antigen receptor (CAR) that recognizes B7-H3 (CD276), as well as methods of use in the treatment of diseases and disorders.

The present invention concerns immunotherapy for cancers having cells that comprise the ganglioside GD2 antigen. In specific embodiment, T cells having a chimeric receptor that targets GD2 is employed. In particular cases, the chimeric receptor comprises antibody, cytoplasmic signaling domain from the T cell receptor, and/or costimulatory molecule(s).

Immunotherapy of cancer using genetically engineered GD2-specific T cells

Growing community of inventors

Chapel Hill, NC, United States of America

Gianpietro Dotti